Meropenem Venus

Meropenem, the active ingredient in Meropenem Venus, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats severe bacterial infections, including pneumonia, intra‑abdominal infections, and sepsis, in hospitalized adult patients.

GNH USA supplies Meropenem Venus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious infections that require intravenous therapy. - Complicated intra‑abdominal infections: provides extensive coverage against Gram‑negative, Gram‑positive and anaerobic bacteria to achieve clinical cure. - Complicated urinary tract infections: eradicates resistant uropathogens, facilitating resolution of infection. - Hospital‑acquired pneumonia: delivers rapid bactericidal activity against typical and atypical respiratory pathogens. - Ventilator‑associated pneumonia: penetrates lung tissue to treat ventilator‑related bacterial colonisation. - Meningitis: achieves therapeutic concentrations in cerebrospinal fluid to treat central nervous system infections. - Severe sepsis and septic shock: offers immediate broad‑spectrum activity to control systemic infection.

Adverse reactions may occur with any intravenous antibiotic and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Headache: transient and usually resolves. - Infusion site phlebitis: pain or redness at the catheter site. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile infection: severe colitis requiring prompt treatment. - Anaphylaxis: acute hypersensitivity reaction with respiratory compromise. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: worsening kidney function in susceptible individuals. - Severe hypersensitivity reactions: including Stevens‑Johnson syndrome.

Prior to initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events. - Renal function assessment: adjust dose in patients with impaired clearance. - Allergy assessment: avoid in individuals with known carbapenem hypersensitivity. - Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. - Concomitant nephrotoxic drugs: monitor renal parameters closely. - Therapeutic drug monitoring: consider in critically ill patients with altered pharmacokinetics. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Valproic acid: increased risk of seizures when combined. - Probenecid: may reduce renal clearance of meropenem, leading to higher plasma levels. - Cytotoxic chemotherapy agents: potential for enhanced toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - Aminoglycosides: increased risk of nephrotoxicity; assess kidney markers. - Anticoagulants (e.g., warfarin): monitor coagulation parameters for potential changes. - Oral contraceptives: reduced efficacy possible; advise alternative contraception. - NSAIDs: watch for additive renal effects.